<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349554</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Acute estradiol and progesterone therapy in hospitalized adults to reduce COVID-19 severity: a randomized control trial.</ArticleTitle><Pagination><StartPage>22732</StartPage><MedlinePgn>22732</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22732</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73263-5</ELocationID><Abstract><AbstractText>COVID-19 outcomes are less severe in women than men suggesting that female sex is protective. The steroids estradiol (E2) and progesterone (P4) promote anti-inflammatory immune responses and their therapeutic use for COVID-19 has been under investigation. The aim of the study was to evaluate the efficacy of a short systemic E2 and P4 combination in mitigating COVID-19 severity in hospitalized men and women. In a phase 2, single center, double blind, randomized placebo-controlled trial, ten male and female participants hospitalized for COVID-19 with scores 3-5 on the 9-point WHO ordinal scale were randomized to receive either (1) E2 cypionate (5 mg, IM) and micronized P4 (200 mg, PO), or (2) placebo-equivalent, in addition to standard of care (SOC). The primary outcome was the proportion of patients whose WHO scores improved to 1-2 on the day of discharge. Secondary outcomes included length of hospital stay (LOS), days on oxygen therapy (DOT), readmission rates (RR), adverse events (AEs), and change in circulating biomarkers using untargeted proteomics and cytokine profiling. There were no significant changes between the groups in primary outcome, LOS, DOT, RR or AEs. The E2P4 group exhibited a decrease in biomarker pathways of respiratory and gastrointestinal disease inflammation, infection by coronavirus, and immune cell trafficking and inflammatory response. A short-term E2P4 treatment in patients hospitalized for COVID-19 decreases biomarkers of inflammation. Considering the availability, low cost, and safety of E2 and P4, our results warrant additional studies to explore their effects in mitigating other viral pandemics. Clinical Trial Registration NCT04865029, ClinicalTrials.gov; (First trial registration 29/04/2021).</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lovre</LastName><ForeName>Dragana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2607-8768</Identifier><AffiliationInfo><Affiliation>Section of Endocrinology and Metabolism, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA. dlovre@tulane.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Endocrinology, Department of Medicine, Southeast Louisiana Veterans Health Care System, New Orleans, LA, 70119, USA. dlovre@tulane.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tulane Center of Excellence in Sex-Based Biology &amp; Medicine, New Orleans, LA, 70112, USA. dlovre@tulane.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qadir</LastName><ForeName>M M Fahd</ForeName><Initials>MMF</Initials><Identifier Source="ORCID">0000-0002-6764-6151</Identifier><AffiliationInfo><Affiliation>Section of Endocrinology and Metabolism, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Endocrinology, Department of Medicine, Southeast Louisiana Veterans Health Care System, New Orleans, LA, 70119, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tulane Center of Excellence in Sex-Based Biology &amp; Medicine, New Orleans, LA, 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8878-4150</Identifier><AffiliationInfo><Affiliation>Section of General Internal Medicine and Geriatrics, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltzman</LastName><ForeName>Leia Y</ForeName><Initials>LY</Initials><Identifier Source="ORCID">0000-0002-2027-6982</Identifier><AffiliationInfo><Affiliation>Tulane University School of Social Work, New Orleans, LA, 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Mya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institutional Review Board - Health Science Research, University of Virginia, Charlottesville, VA, 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauvais-Jarvis</LastName><ForeName>Franck</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0874-0754</Identifier><AffiliationInfo><Affiliation>Section of Endocrinology and Metabolism, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA. fmauvais@tulane.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Endocrinology, Department of Medicine, Southeast Louisiana Veterans Health Care System, New Orleans, LA, 70119, USA. fmauvais@tulane.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tulane Center of Excellence in Sex-Based Biology &amp; Medicine, New Orleans, LA, 70112, USA. fmauvais@tulane.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04865029</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>DK074970</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX003725</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>BX003725</GrantID><Agency>Biomedical Laboratory Research and Development, VA Office of Research and Development</Agency><Country /></Grant><Grant><GrantID>R01 DK074970</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 IK2 CX 002225</GrantID><Agency>Clinical Science Research and Development</Agency><Country /></Grant><Grant><GrantID>IK2 CX002225</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>7-20-COVID-051</GrantID><Agency>American Diabetes Association</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4G7DS2Q64Y</RegistryNumber><NameOfSubstance UI="D011374">Progesterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011374" MajorTopicYN="Y">Progesterone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="Y">Estradiol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Estradiol</Keyword><Keyword MajorTopicYN="N">Estrogen</Keyword><Keyword MajorTopicYN="N">Immune tolerance</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Progesterone</Keyword><Keyword MajorTopicYN="N">Sex differences</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349554</ArticleId><ArticleId IdType="pmc">PMC11442588</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73263-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73263-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. Apr 30 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>2. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. Jul 2020;20(7):442–447. doi:10.1038/s41577-020-0348-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7288618</ArticleId><ArticleId IdType="pubmed">32528136</ArticleId></ArticleIdList></Reference><Reference><Citation>3. Mauvais-Jarvis F. Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19. Diabetes. Sep 2020;69(9):1857–1863. doi:10.2337/dbi19-0023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7458034</ArticleId><ArticleId IdType="pubmed">32669390</ArticleId></ArticleIdList></Reference><Reference><Citation>4. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. Aug 22 2020;396(10250):565–582. doi:10.1016/s0140-6736(20)31561-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7440877</ArticleId><ArticleId IdType="pubmed">32828189</ArticleId></ArticleIdList></Reference><Reference><Citation>5. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama. May 26 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>6. Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. PLoS Pathog. Jun 2020;16(6):e1008570. doi:10.1371/journal.ppat.1008570</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307725</ArticleId><ArticleId IdType="pubmed">32569293</ArticleId></ArticleIdList></Reference><Reference><Citation>7. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. Oct 2016;16(10):626 − 38. doi:10.1038/nri.2016.90</Citation><ArticleIdList><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>8. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. May 2010;10(5):338 − 49. doi:10.1016/s1473-3099(10)70049-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467501</ArticleId><ArticleId IdType="pubmed">20417416</ArticleId></ArticleIdList></Reference><Reference><Citation>9. Phiel KL, Henderson RA, Adelman SJ, Elloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. Feb 15 2005;97(1):107 − 13. doi:10.1016/j.imlet.2004.10.007</Citation><ArticleIdList><ArticleId IdType="pubmed">15626482</ArticleId></ArticleIdList></Reference><Reference><Citation>10. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. Aug 2007;28(5):521 − 74. doi:10.1210/er.2007-0001</Citation><ArticleIdList><ArticleId IdType="pubmed">17640948</ArticleId></ArticleIdList></Reference><Reference><Citation>11. Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes. Endocrinology. Sep 1 2020;161(9)doi:10.1210/endocr/bqaa127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438701</ArticleId><ArticleId IdType="pubmed">32730568</ArticleId></ArticleIdList></Reference><Reference><Citation>12. Costeira R, Lee KA, Murray B, et al. Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study. PLoS One. 2021;16(9):e0257051. doi:10.1371/journal.pone.0257051</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432854</ArticleId><ArticleId IdType="pubmed">34506535</ArticleId></ArticleIdList></Reference><Reference><Citation>13. Seeland U, Coluzzi F, Simmaco M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. Nov 25 2020;18(1):369. doi:10.1186/s12916-020-01851-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685778</ArticleId><ArticleId IdType="pubmed">33234138</ArticleId></ArticleIdList></Reference><Reference><Citation>14. Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K, Fors Connolly AM. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study. BMJ Open. Feb 14 2022;12(2):e053032. doi:10.1136/bmjopen-2021-053032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844968</ArticleId><ArticleId IdType="pubmed">35165090</ArticleId></ArticleIdList></Reference><Reference><Citation>15. Dambha-Miller H, Hinton W, Joy M, Feher M, Lusignan Sd. Mortality in COVID-19 amongst women on Hormone Replacement Therapy or Combined Oral Contraception: A cohort study. medRxiv. 2021:2021.02.16.21251853. doi:10.1101/2021.02.16.21251853</Citation></Reference><Reference><Citation>16. Ghandehari S, Matusov Y, Pepkowitz S, et al. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial. Chest. Jul 2021;160(1):74–84. doi:10.1016/j.chest.2021.02.024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896492</ArticleId><ArticleId IdType="pubmed">33621601</ArticleId></ArticleIdList></Reference><Reference><Citation>17. World Health Organization R&amp;D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. Accessed April 25, 2021. https://www.who.int/teams/blueprint/covid-19</Citation></Reference><Reference><Citation>18. Lovre D, Bateman K, Sherman M, Fonseca VA, Lefante J, Mauvais-Jarvis F. Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial. BMJ Open. Nov 30 2021;11(11):e053684. doi:10.1136/bmjopen-2021-053684</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8635865</ArticleId><ArticleId IdType="pubmed">34848523</ArticleId></ArticleIdList></Reference><Reference><Citation>19. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Bmj. Mar 23 2010;340:c332. doi:10.1136/bmj.c332</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>20. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9(4):e95192. doi:10.1371/journal.pone.0095192</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995906</ArticleId><ArticleId IdType="pubmed">24755770</ArticleId></ArticleIdList></Reference><Reference><Citation>21. Vahidy FS, Pan AP, Ahnstedt H, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One. 2021;16(1):e0245556. doi:10.1371/journal.pone.0245556</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7806140</ArticleId><ArticleId IdType="pubmed">33439908</ArticleId></ArticleIdList></Reference><Reference><Citation>22. Tramunt B, Smati S, Coudol S, et al. Sex disparities in COVID-19 outcomes of inpatients with diabetes: insights from the CORONADO study. Eur J Endocrinol. Jul 5 2021;185(2):299–311. doi:10.1530/eje-21-0068</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494335</ArticleId><ArticleId IdType="pubmed">34085949</ArticleId></ArticleIdList></Reference><Reference><Citation>23. Chen J, Bai H, Liu J, et al. Distinct Clinical Characteristics and Risk Factors for Mortality in Female Inpatients With Coronavirus Disease 2019 (COVID-19): A Sex-stratified, Large-scale Cohort Study in Wuhan, China. Clin Infect Dis. Dec 15 2020;71(12):3188–3195. doi:10.1093/cid/ciaa920</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454470</ArticleId><ArticleId IdType="pubmed">32634830</ArticleId></ArticleIdList></Reference><Reference><Citation>24. Scully EP, Schumock G, Fu M, et al. Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. Open Forum Infect Dis. Sep 2021;8(9):ofab448. doi:10.1093/ofid/ofab448</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8465334</ArticleId><ArticleId IdType="pubmed">34584899</ArticleId></ArticleIdList></Reference><Reference><Citation>25. Sha J, Qie G, Yao Q, et al. Sex Differences on Clinical Characteristics, Severity, and Mortality in Adult Patients With COVID-19: A Multicentre Retrospective Study. Front Med (Lausanne). 2021;8:607059. doi:10.3389/fmed.2021.607059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906985</ArticleId><ArticleId IdType="pubmed">33644092</ArticleId></ArticleIdList></Reference><Reference><Citation>26. Yoshida Y, Gillet SA, Brown MI, et al. Clinical characteristics and outcomes in women and men hospitalized for coronavirus disease 2019 in New Orleans. Biol Sex Differ. Feb 5 2021;12(1):20. doi:10.1186/s13293-021-00359-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7863061</ArticleId><ArticleId IdType="pubmed">33546750</ArticleId></ArticleIdList></Reference><Reference><Citation>27. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. Jul 10 2014;124(2):188 − 95. doi:10.1182/blood-2014-05-552729</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4093680</ArticleId><ArticleId IdType="pubmed">24876563</ArticleId></ArticleIdList></Reference><Reference><Citation>28. Wang X, Tang G, Liu Y, et al. The role of IL-6 in coronavirus, especially in COVID-19. Front Pharmacol. 2022;13:1033674. doi:10.3389/fphar.2022.1033674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9727200</ArticleId><ArticleId IdType="pubmed">36506506</ArticleId></ArticleIdList></Reference><Reference><Citation>29. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Journal of Autoimmunity. 2020/07/01/ 2020;111:102452. doi:https://doi.org/10.1016/j.jaut.2020.102452</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151347</ArticleId><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference><Reference><Citation>30. Sabaka P, Koščálová A, Straka I, et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infectious Diseases. 2021/03/29 2021;21(1):308. doi:10.1186/s12879-021-05945-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8006112</ArticleId><ArticleId IdType="pubmed">33781216</ArticleId></ArticleIdList></Reference><Reference><Citation>31. Yin J-X, Agbana YL, Sun Z-S, et al. Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infectious Diseases of Poverty. 2023/04/24 2023;12(1):43. doi:10.1186/s40249-023-01086-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123579</ArticleId><ArticleId IdType="pubmed">37095536</ArticleId></ArticleIdList></Reference><Reference><Citation>32. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. Feb 15 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>33. Pfeifer P, Voss M, Wonnenberg B, et al. IL-17 C is a mediator of respiratory epithelial innate immune response. Am J Respir Cell Mol Biol. Apr 2013;48(4):415 − 21. doi:10.1165/rcmb.2012-0232OC</Citation><ArticleIdList><ArticleId IdType="pubmed">23221046</ArticleId></ArticleIdList></Reference><Reference><Citation>34. Song X, Zhu S, Shi P, et al. IL-17RE is the functional receptor for IL-17 C and mediates mucosal immunity to infection with intestinal pathogens. Nature Immunology. 2011/12/01 2011;12(12):1151–1158. doi:10.1038/ni.2155</Citation><ArticleIdList><ArticleId IdType="pubmed">21993849</ArticleId></ArticleIdList></Reference><Reference><Citation>35. Lu L, Zhang H, Dauphars DJ, He YW. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends Immunol. Jan 2021;42(1):3–5. doi:10.1016/j.it.2020.10.012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605819</ArticleId><ArticleId IdType="pubmed">33214057</ArticleId></ArticleIdList></Reference><Reference><Citation>36. Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? Lancet Rheumatol. Dec 2020;2(12):e779-e790. doi:10.1016/s2665-9913(20)30340-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546716</ArticleId><ArticleId IdType="pubmed">33073244</ArticleId></ArticleIdList></Reference><Reference><Citation>37. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. Oct 28 2021;385(18):1656–1668. doi:10.1056/NEJMoa2024257</Citation><ArticleIdList><ArticleId IdType="pubmed">34706171</ArticleId></ArticleIdList></Reference><Reference><Citation>38. Madureira G, Soares R. The misunderstood link between SARS-CoV-2 and angiogenesis. A narrative review. Pulmonology. 2023/07/01/ 2023;29(4):323–331. doi:https://doi.org/10.1016/j.pulmoe.2021.08.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390375</ArticleId><ArticleId IdType="pubmed">34593362</ArticleId></ArticleIdList></Reference><Reference><Citation>39. Philippe A, Günther S, Rancic J, et al. VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients. Angiogenesis. 2023/08/01 2023;doi:10.1007/s10456-023-09890-9</Citation><ArticleIdList><ArticleId IdType="pubmed">37526809</ArticleId></ArticleIdList></Reference><Reference><Citation>40. Silva MJA, Ribeiro LR, Gouveia MIM, et al. Hyperinflammatory Response in COVID-19: A Systematic Review. Viruses. Feb 16 2023;15(2)doi:10.3390/v15020553</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9962879</ArticleId><ArticleId IdType="pubmed">36851766</ArticleId></ArticleIdList></Reference><Reference><Citation>41. Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res. Jul 2017;143:142–150. doi:10.1016/j.antiviral.2017.03.022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507769</ArticleId><ArticleId IdType="pubmed">28390872</ArticleId></ArticleIdList></Reference><Reference><Citation>42. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci U S A. Sep 25 2001;98(20):11755-9. doi:10.1073/pnas.201393798</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58802</ArticleId><ArticleId IdType="pubmed">11573010</ArticleId></ArticleIdList></Reference><Reference><Citation>43. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. Jama. Apr 12 2006;295(14):1647-57. doi:10.1001/jama.295.14.1647</Citation><ArticleIdList><ArticleId IdType="pubmed">16609086</ArticleId></ArticleIdList></Reference><Reference><Citation>44. Medina D, Peterson LE, Moraes R, Gay J. Short-term exposure to estrogen and progesterone induces partial protection against N-nitroso-N-methylurea-induced mammary tumorigenesis in Wistar–Furth rats. Cancer Lett. Aug 10 2001;169(1):1–6. doi:10.1016/s0304-3835(01)00507-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11410318</ArticleId></ArticleIdList></Reference><Reference><Citation>45. Lovre D, Qadir, M. M. F., &amp; Mauvais-Jarvis, F. Data from: E2P4 COVID19 Trial Cytokine profile data. 2024. Zenodo. doi:https://doi.org/10.5281/zenodo.10570139</Citation></Reference><Reference><Citation>46. Lovre D, Qadir, M. M. F.,, &amp; Mauvais-Jarvis F. Data from: E2P4 COVID19 2024 Manuscript. 2024. doi:https://zenodo.org/doi/10.5281/zenodo.10570112</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>